Introduction: Perception of illness varies among individuals and psoriasis of the same severity can be perceived in different ways by patients, making it essential to evaluate quality of life (QoL) since it can provide information on the impact of the disease on the patient's overall well-being. The use of patient-reported outcomes in clinical trials provides the ability to integrate objective clinical assessment with the patient's perception of their own state of health. Areas covered: The introduction of anti-IL17 agents in clinical practice has given patients the possibility to achieve a PASI90 response (almost clear skin) or even higher (complete clear skin) in the majority of patients. There is accumulating evidence in support of PASI90 response as the new standard goal for therapy based on its greater correlation with health-related QoL. The present review summarizes current knowledge of the effects of secukinumab on the QoL of patients with psoriasis using patient-reported outcome measures. Expert Opinion: Secukinumab, the first approved drug of this new class, has fully reached a new therapeutic paradigm not only in terms of clinical efficacy, but also in terms of patient satisfaction and self-rated health.

Galluzzo, M., Talamonti, M., Manfreda, V., Silvaggio, D., Tartaglia, C., Roberto, D., et al. (2020). Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies. EXPERT OPINION ON BIOLOGICAL THERAPY [10.1080/14712598.2021.1849131].

Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies

Galluzzo, Marco;Talamonti, Marina;Campione, Elena;Bianchi, Luca
2020-11-27

Abstract

Introduction: Perception of illness varies among individuals and psoriasis of the same severity can be perceived in different ways by patients, making it essential to evaluate quality of life (QoL) since it can provide information on the impact of the disease on the patient's overall well-being. The use of patient-reported outcomes in clinical trials provides the ability to integrate objective clinical assessment with the patient's perception of their own state of health. Areas covered: The introduction of anti-IL17 agents in clinical practice has given patients the possibility to achieve a PASI90 response (almost clear skin) or even higher (complete clear skin) in the majority of patients. There is accumulating evidence in support of PASI90 response as the new standard goal for therapy based on its greater correlation with health-related QoL. The present review summarizes current knowledge of the effects of secukinumab on the QoL of patients with psoriasis using patient-reported outcome measures. Expert Opinion: Secukinumab, the first approved drug of this new class, has fully reached a new therapeutic paradigm not only in terms of clinical efficacy, but also in terms of patient satisfaction and self-rated health.
27-nov-2020
Online ahead of print
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
illness perception
patient-reported outcomes
quality of life
secukinumab
self-rated health
Galluzzo, M., Talamonti, M., Manfreda, V., Silvaggio, D., Tartaglia, C., Roberto, D., et al. (2020). Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies. EXPERT OPINION ON BIOLOGICAL THERAPY [10.1080/14712598.2021.1849131].
Galluzzo, M; Talamonti, M; Manfreda, V; Silvaggio, D; Tartaglia, C; Roberto, D; Campione, E; Bianchi, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
galluzzo-impact of secukinumab.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 8.27 MB
Formato Adobe PDF
8.27 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/259996
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact